NEOSS LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to note 1.2 in the financial statements, which indicates that under management's severe but plausible forecasts, the group's ability to continue to meet its liabilities as they fall due during the going concern assessment period is dependent on obtaining additional financing. The additional financing is not yet formally in place. As stated in note 1.2, these events or conditions, along with the other matters as set forth in note 1.2, indicate that a material uncertainty exists that may cast significant doubt on the group's and the parent company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -13.7%

  £31,675,763 → £27,333,292

• Cash

  +57.7%

  £1,733,988 → £2,735,083

• Net assets

  +157.3%

  -£15,390,458 → £8,822,414

• Employees

  -17.6%

  170 → 140

• Operating profit

  +67.7%

  -£10,564,805 → -£3,413,248

• Profit before tax

  +72.6%

  -£12,471,894 → -£3,411,948

• Wages

  -23.7%

  £12,946,443 → £9,875,944

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. NEOSS LIMITED 2003-06-10 → present
2. OSSEOBIOTEK LIMITED 2000-11-30 → 2003-06-10

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 1.2 in the financial statements, which indicates that under management's severe but plausible forecasts, the group's ability to continue to meet its liabilities as they fall due during the going concern assessment period is dependent on obtaining additional financing. The additional financing is not yet formally in place. As stated in note 1.2, these events or conditions, along with the other matters as set forth in note 1.2, indicate that a material uncertainty exists that may cast significant doubt on the group's and the parent company's ability to continue as a going concern.”

Group structure

1. NEOSS LIMITED · parent
   1. Neoss GmbH 100% · Germany · Dental Implants
   2. Neoss Australia Pty. Ltd 100% · Australia · Dental Implants
   3. Neoss Italia S.r.l 100% · Italy · Dental Implants
   4. Neoss AB 100% · Sweden · Head Office Function
   5. Neoss Inc. 100% · USA · Dental Implants
   6. Neoss Shanghai 100% · China · Dental Implants
   7. Neoss UK & Ireland Limited 100% · UK · Dental Implants
   8. Neoss Norden AB 100% · Sweden · Dental Implants
   9. Neoss AG 100% · Switzerland · Head Office Function
   10. Arc Solutions AB 100% · Sweden · Milling of Restorations

Significant events

• “In September 2024, the company reached an agreement with its investors to convert the outstanding debt into equity, strengthening the Group's balance sheet and improving its liquidity position. Additionally, the current investors made a further equity injection in the same month.”
• “After the year end, the Company entered into a new bank loan agreement providing additional funding to enhance liquidity and support planned investments in production capacity, digital infrastructure, and market expansion activities.”
• “In April and June 2025 Neoss entered into two new loans, further details can be found in note 25.”
• “In June 2025 Neoss entered a term loan with HSBC for £1.75m. This loan is repayable in 60 monthly payments and funds were drawn down in August 2025. The interest rate on this loan is linked to base rate.”
• “In April 2025 Neoss entered into a loan with GHP Healthcare Holdings Limited for £1.2m. This loan is repayable upon the 3rd anniversary of its drawdown. The interest rate on this loan is 6.5%.”
• “During 2024 the company entered into an agreement with its investors to convert £22,308,744 of outstanding debt into Ordinary Shares. The company issued 46,372,399 Ordinary shares with a par value of £0.001 in exchange for the full settlement of the debt. Ordinary share classes A-D were also removed as part of the above agreement. Also during 2024, the company received an equity injection of £5,890,133 from the existing investors. This injection was in exchange for the issuance of 12,243,052 new Ordinary shares at a price of £0.48 per share.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

7

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.